Darren –
First, Japan’s health ministry acknowledged the growing rate of heart inflammation among the vaccinated population. Then Japan’s public and private sectors were alerted to the fact and forbidden to discriminate against those who refuse the COVID vaccine. Furthermore, Japan has made it clear that “informed consent” is required to receive the vaccine. Japan now insists the vaccine labels warn of dangerous potential side effects such as myocarditis.
_____________
NHK-Japan (Japan Broadcasting Corporation) | Japan’s health ministry has listed inflammation of the heart muscle and of the outer lining of the heart in younger males as possible serious side effects of the Moderna and Pfizer COVID vaccines.
It says that as of November 14, out of every one million males who had the Moderna vaccine, such side effects were reported in 81.79 males aged 10 to 19 and 48.76 males in their 20s.
The figures were 15.66 and 13.32 respectively for those who had the Pfizer vaccine. The ministry held a panel of expert on Saturday [Dec. 4] and proposed warning of the risk by printing “serious side effects” on the documents attached to the vaccines. It will also require hospitals to report in detail incidents involving people who developed the symptoms within 28 days after being vaccinated, according to the law. The plan was approved by the panel, and the ministry will notify municipalities.
__________________
RairFoundation.com | Japan announces that public and private sectors can not discriminate against those who refuse the experimental mRNA gene therapy injections.
Japan is now labeling Covid “vaccines” to warn of dangerous and potentially deadly side effects such as myocarditis. In addition, the country is reaffirming its commitment to adverse event reporting requirements to ensure all possible side effects are documented. These efforts from Japan’s health authority are in stark contrast to the deceptive measures taken by other countries to coerce citizens into taking the injection, downplaying side effects, and discouraging proper adverse event reporting.
